Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial

  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Fernández, Marco A.|||0000-0002-3921-2209
  • Marszalek, Marta
  • Coll, Pep
  • Manzardo, Christian
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • Miró, José M.|||0000-0001-8057-7755
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Brander, Christian|||0000-0002-0548-5778
Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4 + T cells from HIV-1 + individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the immune system elimination of infected cells after inducing HIV-1 viral reactivation, may be limited. In order to address whether the in vitro observations are replicated in vivo, we determined the effects of RMD on the total and HIV-1-specific T-cell populations in longitudinal samples from the BCN02 kick&kill clinical trial (NCT02616874). BCN02 was a proof-of-concept study in 15 early treated HIV-1 + individuals that combined MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency reversing agent. Our results show that RMD induced a transient increase in the frequency of apoptotic T cells and an enhanced activation of vaccine-induced T cells. Although RMD reduced the number of vaccine-elicited T cells secreting multiple cytokines, viral suppressive capacity of CD8 + T cells was preserved over the RMD treatment. These observations have important implications for the design of effective kick&kill strategies for the HIV-1 cure.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals, Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)

  • Mothe, Beatriz|||0000-0001-9975-407X
  • Rosás-Umbert, Miriam|||0000-0002-2850-6586
  • Coll, Pep
  • Manzardo, Christian
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Moron-Lopez, Sara|||0000-0003-0800-9205
  • Llano Montero, Anuska|||0000-0002-0133-9888
  • Miranda, Cristina
  • Cedeño, Samandhy|||0000-0001-8312-0208
  • López, Miriam
  • Alarcón-Soto, Yovaninna|||0000-0002-9977-8634
  • Melis, Guadalupe Gómez
  • Langohr, Klaus|||0000-0001-7075-9192
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Toro, Jessica
  • Ruiz, Irene
  • Rovira, Cristina
  • Carrillo, Antonio
  • Meulbroek, Michael
  • Crook, Alison
  • Wee, Edmund G.
  • Miró, José M.|||0000-0001-8057-7755
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Valle, Marta|||0000-0002-3515-251X
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Hanke, Tomáš|||0000-0002-6076-9546
  • Brander, Christian|||0000-0002-0548-5778
  • Moltó, José|||0000-0003-4564-1963
Kick&kill strategies combining drugs aiming to reactivate the viral reservoir with therapeutic vaccines to induce effective cytotoxic immune responses hold potential to achieve a functional cure for HIV-1 infection. Here, we report on an open-label, single-arm, phase I clinical trial, enrolling 15 early-treated HIV-1-infected individuals, testing the combination of the histone deacetylase inhibitor romidepsin as a latency-reversing agent and the MVA.HIVconsv vaccine. Romidepsin treatment resulted in increased histone acetylation, cell-associated HIV-1 RNA, and T-cell activation, which were associated with a marginally significant reduction of the viral reservoir. Vaccinations boosted robust and broad HIVconsv-specific T cells, which were strongly refocused toward conserved regions of the HIV-1 proteome. During a monitored ART interruption phase using plasma viral load over 2,000 copies/ml as a criterium for ART resumption, 23% of individuals showed sustained suppression of viremia up to 32 weeks without evidence for reseeding the viral reservoir. Results from this pilot study show that the combined kick&kill intervention was safe and suggest a role for this strategy in achieving an immune-driven durable viremic control.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gut microbiome signatures linked to HIV-1 reservoir size and viremia control

  • Borgognone, Alessandra|||0000-0001-5487-3016
  • Noguera-Julian, Marc|||0000-0002-6194-1395
  • Oriol-Tordera, Bruna|||0000-0002-2714-9097
  • Noël-Romas, Laura
  • Ruiz Riol, Marta|||0000-0003-1899-8879
  • Guillén, Yolanda|||0000-0001-8673-6470
  • Parera, Mariona|||0000-0002-0756-8307
  • Casadellà, Maria|||0000-0002-4115-2305
  • Duran-Castells, Clara|||0000-0002-4034-5738
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Català-Moll, Francesc|||0000-0002-2354-8648
  • De Leon, Marlon
  • Knodel, Samantha
  • Birse, Kenzie
  • Manzardo, Christian
  • Miró, José M.|||0000-0001-8057-7755
  • Clotet Sala, Bonaventura|||0000-0003-3232-4598
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Moltó, José|||0000-0003-4564-1963
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Burgener, Adam
  • Brander, Christian|||0000-0002-0548-5778
  • Paredes, Roger|||0000-0002-6553-691X
The potential role of the gut microbiome as a predictor of immune-mediated HIV-1 control in the absence of antiretroviral therapy (ART) is still unknown. In the BCN02 clinical trial, which combined the MVA.HIVconsv immunogen with the latency-reversing agent romidepsin in early-ART treated HIV-1 infected individuals, 23% (3/13) of participants showed sustained low-levels of plasma viremia during 32 weeks of a monitored ART pause (MAP). Here, we present a multi-omics analysis to identify compositional and functional gut microbiome patterns associated with HIV-1 control in the BCN02 trial. Viremic controllers during the MAP (controllers) exhibited higher Bacteroidales/Clostridiales ratio and lower microbial gene richness before vaccination and throughout the study intervention when compared to non-controllers. Longitudinal assessment indicated that the gut microbiome of controllers was enriched in pro-inflammatory bacteria and depleted in butyrate-producing bacteria and methanogenic archaea. Functional profiling also showed that metabolic pathways related to fatty acid and lipid biosynthesis were significantly increased in controllers. Fecal metaproteome analyses confirmed that baseline functional differences were mainly driven by Clostridial es. Participants with high baseline Bacteroidales/Clostridiales ratio had increased pre-existing immune activation-related transcripts. The Bacteroidales/Clostridiales ratio as well as host immune-activation signatures inversely correlated with HIV-1 reservoir size. The present proof-of-concept study suggests the Bacteroidales/Clostridiales ratio as a novel gut microbiome signature associated with HIV-1 reservoir size and immune-mediated viral control after ART interruption. The online version contains supplementary material available at 10.1186/s40168-022-01247-6.